University of California San Diego School of Medicine, 9350 Campus Point Drive, La Jolla, CA 92037, USA.
J Rheumatol. 2010 Mar;37(3):650-5. doi: 10.3899/jrheum.090575. Epub 2010 Jan 15.
OBJECTIVE: To assess whether inflammation on ultrasound is predictive of clinical response to intraarticular (IA) corticosteroid injections in patients with knee osteoarthritis (OA). METHODS: Patients with symptomatic knee OA were randomized to receive either an IA injection of 40 mg triamcinolone acetonide in the treatment group or 1 cc 0.9% saline in the placebo group. Clinical response was assessed by changes in baseline Western Ontario and McMaster Universities (WOMAC) index scores and physician global assessment at 4 and 12 weeks. Ultrasounds were performed at each visit. Patients and assessors were blinded to treatment status. RESULTS: Seventy-nine patients were enrolled into the study. Four-week data were available for 67 patients in the primary analysis comparing change in WOMAC pain score from baseline to 4 weeks. There was almost no change in the WOMAC pain subscale score from baseline to 4 weeks in the control group, but there was a significant improvement in WOMAC pain subscale score from 10.8 (SD +/- 3.2) at baseline to 8.75 (SD +/- 4.0) at 4 weeks in the treatment group (adjusted p = 0.001). Of the 34 patients in the treatment group; 16 (47%) had inflammatory disease and 18 (53%) had noninflammatory disease as determined by ultrasound. There was no difference in the change in WOMAC pain score between the inflammatory and noninflammatory patients in the treatment group at 4 weeks. There was a statistically significant greater improvement in pain subscale scores among noninflammatory patients than among inflammatory patients at 12 weeks. CONCLUSION: Intraarticular corticosteroid injections are an effective short-term treatment for symptomatic knee OA compared to placebo. Patients with noninflammatory characteristics on ultrasound had a more prolonged benefit from IA corticosteroids compared to inflammatory patients.
目的:评估膝关节骨关节炎(OA)患者关节内(IA)皮质类固醇注射后的炎症是否与临床反应相关。
方法:将有症状的膝关节 OA 患者随机分为治疗组(接受 40mg 曲安奈德的 IA 注射)或安慰剂组(接受 1cc 生理盐水 IA 注射)。通过基线 Western Ontario 和 McMaster 大学(WOMAC)指数评分和 4 周及 12 周时医生整体评估的变化来评估临床反应。每次就诊时均进行超声检查。患者和评估者均对治疗状况进行盲法。
结果:79 名患者入组本研究。主要分析中,有 67 名患者可提供基线至 4 周时 WOMAC 疼痛评分变化的 4 周数据。对照组的 WOMAC 疼痛亚量表评分从基线到 4 周几乎没有变化,但治疗组的 WOMAC 疼痛亚量表评分从基线的 10.8(SD +/- 3.2)显著改善至 4 周时的 8.75(SD +/- 4.0)(调整后的 p = 0.001)。在治疗组的 34 名患者中;16 名(47%)患者的疾病为炎症性,18 名(53%)患者的疾病为非炎症性,通过超声确定。在治疗组中,4 周时炎症和非炎症患者的 WOMAC 疼痛评分变化无差异。在治疗组中,非炎症患者的疼痛亚量表评分在 12 周时的改善程度明显大于炎症患者。
结论:与安慰剂相比,IA 皮质类固醇注射是治疗膝关节 OA 症状的有效短期治疗方法。超声显示非炎症特征的患者接受 IA 皮质类固醇治疗的获益时间比炎症患者更长。
Cochrane Database Syst Rev. 2005-4-18
Life (Basel). 2025-7-19
Musculoskeletal Care. 2025-6
Ital J Pediatr. 2025-3-24
Arthritis Care Res (Hoboken). 2024-2
Nat Rev Rheumatol. 2022-5
Am Health Drug Benefits. 2021-6